Primary Site >> Biliary tract Cancer

Gene >> RRM1

Journal: Oncol Rep. 2008 Aug;20(2):279-86.
Title: Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
Author: Ohtaka, Kazuma|Kohya, Naohiko|Sato, Ken|Kitajima, Yoshihiko|Ide, Takao|Mitsuno, Mayumi|Miyazaki, Kohji
PMID: 18636187
Journal: Lancet Oncol. 2011 Jul;12(7):693-702.
Title: The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer.
Author: Jordheim, Lars Petter|Seve, Pascal|Tredan, Olivier|Dumontet, Charles
PMID: 21163702
Journal: Hepatogastroenterology. 2011 Sep-Oct;58(110-111):1659-63.
Title: Ribonucleotide reductase M1 expression in intrahepatic cholangiocarcinoma.
Author: Wakai, Toshifumi|Shirai, Yoshio|Sakata, Jun|Takamura, Masaaki|Matsuda, Yasunobu|Korita, Pavel V|Muneoka, Katsuki|Sasaki, Masataka|Ajioka, Yoichi|Hatakeyama, Katsuyoshi
PMID: 21940346
Journal: Invest New Drugs. 2012 Dec;30(6):2148-60.
Title: The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines.
Author: Nam, Hyun-Jin|Kim, Hwang-Phill|Yoon, Young-Kwang|Song, Sang-Hyun|Min, Ah-Rum|Han, Sae-Won|Im, Seock-Ah|Kim, Tae-You|Oh, Do-Youn|Bang, Yung-Jue
PMID: 22197904
Journal: Cancer. 2013 Jan 15;119(2):454-62.
Title: Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Author: Fisher, Sarah B|Fisher, Kevin E|Patel, Sameer H|Lim, Matthew G|Kooby, David A|El-Rayes, Bassel F|Staley, Charles A 3rd|Adsay, N Volkan|Farris, Alton B 3rd|Maithel, Shishir K
PMID: 22760605
Journal: World J Surg Oncol. 2013 May 27;11:117.
Title: Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone.
Author: Murata, Akihiro|Amano, Ryosuke|Yamada, Nobuya|Kimura, Kenjiro|Yashiro, Masakazu|Nakata, Bunzo|Hirakawa, Kosei
PMID: 23710668
Journal: Br J Cancer. 2014 Sep 23;111(7):1275-84.
Title: Concurrent analysis of human equilibrative nucleoside transporter 1 and ribonucleotide reductase subunit 1 expression increases predictive value for prognosis in cholangiocarcinoma patients treated with adjuvant gemcitabine-based chemotherapy.
Author: Sasaki, H|Murakami, Y|Uemura, K|Sudo, T|Hashimoto, Y|Kondo, N|Sueda, T
PMID: 25032731
Journal: Int J Clin Exp Med. 2014 Dec 15;7(12):5041-9. eCollection 2014.
Title: Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.
Author: Deng, Ting|Pan, Hong|Han, Rubing|Huang, Dingzhi|Li, Hongli|Zhou, Likun|Wang, Xia|Bai, Ming|Li, Xiang|Liu, Rui|Ge, Shaohua|Ning, Tao|Zhang, Le|Ba, Yi
PMID: 25664003
Journal: HPB (Oxford). 2015 Dec;17(12):1119-23.
Title: Intrahepatic cholangiocarcinoma and gallbladder cancer: distinguishing molecular profiles to guide potential therapy.
Author: Potkonjak, Mary|Miura, John T|Turaga, Kiran K|Johnston, Fabian M|Tsai, Susan|Christians, Kathleen K|Gamblin, T Clark
PMID: 26374242
Journal: Oncology. 2015;89(6):345-50.
Title: Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Author: Yoon, Kyong-Ah|Woo, Sang Myung|Hong, Eun Kyung|Jung, Mee Kyung|Park, Weon Seo|Bae, Kieun|Han, Sung-Sik|Kim, Tae Hyun|Koh, Young Hwan|Park, Sang-Jae|Lee, Woo Jin
PMID: 26418006
Journal: Oncotarget. 2017 Jul 6;8(46):81394-81404.
Title: DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.
Author: Woo, Sang Myung|Yoon, Kyong-Ah|Hong, Eun Kyung|Park, Weon Seo|Han, Sung-Sik|Park, Sang-Jae|Joo, Jungnam|Park, Eun Young|Lee, Ju Hee|Kim, Yun-Hee|Kim, Tae Hyun|Lee, Woo Jin
PMID: 29113399